Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 22 for “"Exemestane"”.
-
Influence of the UGT2B17 Gene on the Relationship Between Exemestane and Bone Mineral Density in Postmenopausal Women
… (MAP.3) randomized placebo-controlled trial of exemestane, postmenopausal women experienced a loss in bone mineral density (BMD). UGT2B17 facilitates excretion of androgens and exemestane. For Caucasian postmenopausal women, this gene deletion is hypothesized to have 1) a protective effect on …
-
The associations between estrogens, the UGT2B17 gene deletion, and health-related quality of life in postmenopausal women in the MAP.3 chemoprevention trial
… quality of life (HRQL). For women taking exemestane in the Mammary Prevention 3 (MAP.3) trial, symptoms may have been exacerbated, as exemestane works to further suppress estrogen levels to prevent breast cancer. Women with the UGT2B17 gene deletion have limited ability to metabolize and …
-
The Effect of Exemestane on Menopause-Specific Health-Related Quality of Life and a Comparison With Clinician-Reported Toxicities: an Analysis of the NCIC CTG MAP.2 Chemoprevention Trial
Background: Exemestane is a drug of great interest for breast cancer prevention, because it inhibits estrogen production. Estrogen may operate by increasing breast density, a well-established biomarker for increased breast cancer risk. The NCIC CTG MAP.2 trial examined the efficacy of exemestane in …
-
Μελέτη του μηχανισμού δράσης αναστολέων της αρωματάσης και του υποδοχέα του επιδερμικού αυξητικού παράγοντα (EGFR) σε μη μικροκυτταρικό καρκίνο του πνεύμονα
… crucial. This study investigates the effect of exemestane, an aromatase inhibitor, and erlotinib, an EGFR inhibitor, on human NSCLC cell lines; H23, H358 and A549. A cell proliferation assay was used for measuring cell number, apoptosis assay for detecting apoptosis and necrosis and …
-
UGT2B17, exemestane metabolism, and their association with physical health-related quality of life in Caucasian postmenopausal women participating in the Mammary Prevention.3 Trial
… In the Mammary Prevention.3 (MAP.3) trial of exemestane (EXE) for breast cancer prevention, postmenopausal women commonly reported physical menopause-related symptoms, such as joint and muscle pain and fatigue. UGT2B17 contributes to the elimination of EXE-induced activity; however, …
-
The Association between the UGT2B17 Gene Deletion and Menopause-Related Quality of Life in Postmenopausal Women in the CCTG MAP.3 Breast Cancer Chemoprevention Trial
… was a randomized placebo controlled trial of exemestane for breast cancer prevention. Participants commonly experienced vasomotor symptoms, such as hot flashes. Exemestane is ultimately eliminated through glucuronidation activity by UGT2B17; approximately 10% of Caucasians are homozygous null …
-
The Effect of Vaginal Estrogen on Circulating Estrogen and Breast Cancer Risk in Postmenopausal Women Participating in the MAP.3 Breast Cancer Prevention Trial
… post-randomization (placebo (n=1,682) or exemestane (n=1,544)). VE use was self-reported and annual mammograms recorded breast cancer events. Multiple linear regression modeling was conducted to investigate the association between VE use and serum estrogen at baseline and recent VE use at …
-
Avaliação citológica em base líquida de fármacos moduladores estrogênicos
… maturation (diestrais), while anastrozole and exemestane increased the duration of the phases of larger maturation (estrais). The data were analysed through a cubical non linear regression (spline) which allowed a better characterization of the drugs, suggesting a proper cytological profile to …
-
Examining the Relationship Between Insulin-Like Growth Factor-I and Breast Density in Post-Menopausal Women
… a clinical trial that analyzed the efficacy of exemestane in reducing breast cancer risk. Cumulus software was used to calculate percent breast density values from provided mammograms. These values were then dichotomized as being either low (< 25%) or moderately high (≥ 25%). IGF-I …
-
Factors Associated With Worsening Menopause-Specific Health-Related Quality of Life and Treatment Discontinuation in a Breast Cancer Chemoprevention Trial
… randomized placebo-controlled trial evaluating exemestane for breast cancer prevention demonstrated a 65% relative reduction in invasive breast cancer incidence. Up to 50% of participants in both trial arms reported a clinically meaningful worsening in their menopause-specific health-related …
-
Vitamin D and mammographic density in postmenopausal women: A cohort study nested within a chemoprevention trial
… latitudes. Potential effect modification by exemestane therapy, calcium or genetic polymorphisms in the vitamin D pathway was also examined. Methods: This study evaluated a sub-cohort of postmenopausal women at elevated BC risk who participated in the NCIC Clinical Trials Group …
-
Hormonal factors and insulin-like growth factor-1 in North American postmenopausal women
… 2. Changes in IGF-1 were compared between the exemestane and placebo, and effect modification by BMI was tested with an interaction term. Results: Objective 1. Women aged 55 years or older at menopause had 16.26 ng/mL (95% CI: 1.76, 30.75) higher IGF-1 compared to women aged less than 50 years …
-
Statistical modelling of biomarkers incorporating non-proportional effects for survival data: with illustration by application to two residual risk models for predicting risk in early breast cancer
… Series (BCS) and the Tamoxifen versus Exemestane Adjuvant Multinational (TEAM) trial. Similar results were observed between the two approaches that were considered, the multivariable fractional polynomial time (MFPT) approach and Royston-Parmer flexible parametric models, with their …
-
A Mechanistic Modeling Framework for Pharmacogenomics-Informed Prediction of Bone Toxicity
… was used to simulate long-term BMD loss during exemestane treatment, evaluate the impact of denosumab and romosozumab interventions, and examine genetic contributions to heterogeneity in treatment response. The developed model successfully reproduced observed trends in bone loss during aromatase …
-
Estrogen’s Impact on the Specialized Transcriptome, Brain, and Vocal Learning Behavior of a Sexually Dimorphic Songbird
… females. I treated animals with either vehicle, exemestane (an estrogen synthesis inhibitor), or 17-β-estradiol from the moment of hatching until time of sacrifice. I collected the song learning nuclei and their surrounding brain regions during the onset of sensory motor learning for …
-
Συστηματική ανασκόπηση της αποτελεσματικότητας και της ασφάλειας του Giredestrant στη θεραπεία του καρκίνου του μαστού - Systematic review on the efficacy and safety of Giredestrant for breast cancer therapy
… νόσου με giredestrant + everolimus έναντι exemestane + everolimus μετά από πρόοδο υπό CDK4/6-αναστολείς. Τρεις επιπλέον μελέτες φάσης III (lidERA BC, persevERA BC, pionERA BC) βρίσκονται σε εξέλιξη. Το giredestrant ήταν γενικώς καλά ανεκτό, με τις περισσότερες ανεπιθύμητες ενέργειες να …
-
THE ROLES OF DHEA-S AND AKR1C3 VARIANTS IN AKR1C3-MEDIATED PROSTATE CANCER DRUG RESISTANCE
… reported major differences in metabolism of exemestane, an aromatase inhibitor used to treat breast cancer, by variants H5Q, E77G, K104D, and R258C compared to WT. To determine if nsSNPs could impact AKR1C3’s role in CRPC, we purified AKR1C3 H5Q, E77G, K104D, and R258C from E. coli to …
-
Aromatase inhibitors produce hypersensitivity in experimental models of pain : studies in vivo and in isolated sensory neurons
… mg/kg letrozole or daily dosing of letrozole or exemestane in male rats augments flinching behavior induced by intraplantar ATP injection. To determine whether the effects of AIs on nociceptive behaviors are mediated by activation or sensitization of peptidergic sensory neurons, I determined …
-
Polymorphisms in the GSTA1 and UGT2B17 genes, estrogen levels and menopause-related side effects among post-menopausal women participating in the MAP.3 trial
… The Mammary Prevention.3 (MAP.3) trial evaluated exemestane (EXE) for breast cancer prevention, where menopause-related symptoms such as joint pain, fatigue, and hot flashes were common. Genetic variation in detoxification enzyme genes, including GSTA1 and UGT2B17, may influence estrogen …
-
Διερεύνηση και κλινική αξιολόγηση νέων δεικτών μεθυλίωσης του DNA στον καρκίνο, στα πλαίσια της υγρής βιοψίας
… associated with lack of response to everolimus/exemestane treatment. We additionally developed and clinically validated an assay for MLL3 promoter methylation as a novel circulating epigenetic biomarker in non-small cell lung cancer (NSCLC). Our data indicate for the first time that the …
Page 1 of 2